PATENT CLAIM ANALYSIS

Application Number: 16012536
Application Type: Utility
Filing Date: 2018-06
Publication Date: 2018-10
Patent Classification: ["514", "364000"]

Abstract:
The invention describes compounds that inhibit both HDAC and GSK3β (i.e., HDAC/GSK3β dual inhibitors). The invention further describes compositions containing these HDAC/GSK3β dual inhibitors, as well as methods and kits using these HDAC/GSK3β dual inhibitors to treat various medical conditions. The invention also provides methods and kits using a HDAC inhibitor and a GSK3β to treat various medical conditions, and compositions containing a HDAC inhibitor and a GSK3β. Medical conditions treatable with various embodiments of the invention include but are not limited to cancers and tumors.

Claim (Index 108):
A method of treating a cancer or tumor in a subject, comprising: administering a therapeutically effective amount of a compound of Formula (V): wherein:\n L 1  and L 2  are independently a linker; \n R 1  is an aromatic moiety, alkyl, acyl, cyclyl or heterocyclyl, each of which is optionally substituted; \n R 2  is lower alkyl, cyclyl, heterocyclyl, aryl, or heteroaryl, each of which is optionally substituted, or hydrogen; \n R 3  is an aromatic moiety, which is optionally substituted; and \n p is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10.

Metadata:
- Claim Count in Document: 51.0
- Percentile: 94.0
- Lexical Diversity: 1.93878
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15317559', '14510711', '14088804', '12339492', '15834052']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7676313589044887
- 35 USC 102 Novelty (BERT): 0.5918036923474418
- Combined Prediction Score: 0.7500485922487841
- Mean Citation Score: 302.1332940000001
- Max Citation Score: 580.7595
- Similarity Product: 405.5257377877235

Labels:
- Claim Label 101: 1
- Claim Label 102: 0
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 0
- Label 101 Adjusted: 1

Dataset: test